Identification of mutations in genes such as BRAFV600E, TERT promoter, RAS, and RET fusions furnishes robust evidence for adjunctive diagnosis, elucidation of tumor biology, prognostic stratification, and the implementation of targeted therapy for patients afflicted with advanced PTC, high-grade thyroid follicular epithelium-derived neoplasms, and undifferentiated carcinomas [8,9]. This evidence concerns the gene RET and neoplasm.